There are four primary mesothelioma stages that doctors use to identify the seriousness of a mesothelioma diagnosis, labeled stage I, II, III or IV. The staging systems used to identify what stage of mesothelioma a patient has are the Brigham, TNM or Butchart systems. The lower stage number you’re given, the more treatment options you have, and the better your chances are for long-term survival.
Staging is an accepted way for cancer doctors to describe to patients – and to one another – how advanced the disease is, how prevalent tumors are and how far the cancer has spread. Given the aggressive nature of the cancer, mesothelioma staging is a key part of proper diagnosis and treatment.
Why is mesothelioma staging important? Because knowing where a cancer is in its development sets the table for treatment, which treatment options are available and which are not. For example, doctors use cancer stage as a guideline when deciding whether a patient is likely to benefit from surgery.
If a patient is healthy enough for aggressive treatment and doctors believe that all visible signs of cancer can be completely removed, they say the cancer is resectable and will likely recommend a treatment plan involving surgery. If the spread of cancer is too advanced, however, and can’t be removed completely, the cancer is unresectable. In this situation, doctors will recommend other treatment options, including chemotherapy and experimental treatments.
Stage I pleural mesotheliomas are generally resectable, as well as some diagnosed at stage II and III. But by stage IV, the cancer can't be removed completely with surgery. The cancer's subtype can also affect treatment options because most doctors agree surgery doesn't help with sarcomatoid mesotheliomas.
When peritoneal mesotheliomas have spread beyond the abdomen, surgery likely is not helpful. Doctors consider peritoneal mesothelioma unresectable when it has invaded certain areas within the abdomen, including:
If the cancer has spread to these locations, doctors typically deliver chemotherapy to the entire body or directly to the abdomen.
Free information, books, wristbands and more for patients and caregivers.Get Your Free Guide Get Your Free Mesothelioma Guide
The different stages of cancer provide vital information for oncologists (cancer doctors) who treat mesothelioma, but all experts agree universally on one principle: It's preferable to catch cancer, specifically mesothelioma, in the earliest stage possible.
Many specialists who treat these cancers — even some of the most respected ones in the field — don't agree on one staging system. Although many doctors agree that the stage of mesothelioma a patient has is a strong predictor of lifespan, not all do.Learn More About Staging Methods
If you are diagnosed with mesothelioma, you should seek a second opinion. Oncologists treat a variety of cancers, but they may not have experience with staging asbestos-related cancers. Always find a doctor who does.Get Help Finding A Specialist
Using one of three systems, doctors will assign your cancer a stage of I through IV. The stage varies depending on several factors, including the size and location of your tumor and whether it has spread to lymph nodes or distant organs.
Doctors use three primary systems for mesothelioma staging: Brigham, TNM, and Butchart. These systems are used primarily for pleural mesothelioma staging because there are currently no formal staging systems for the other types. TNM and Brigham are the most-used by mesothelioma specialists, although some doctors believe that none are accurate enough.
Stage I typically offers the best chance for survival because of the potentially curative surgical treatments available for patients. Most stage I patients qualify for extrapleural pneumonectomy, an aggressive surgery that attempts to remove as much of the tumor growth as possible. Surgeons take out an entire diseased lung and other tissues, including the diaphragm, nearby lymph nodes and the linings of the chest and heart.
At this stage of progression, most doctors only recommend palliative treatments because the cancer has spread to many parts of the body. Trying to remove all the tumors is too difficult, and many patients are too weak to withstand aggressive treatments. Palliative treatments, which focus on symptoms rather than curing the disease, can ease pain and suffering and improve quality of life.
Because of the nature of mesothelioma and the way the cancer grows and spreads, most people are not diagnosed until stage III or IV. Doctors usually treat asbestos-related cancers with a combination of chemotherapy, radiotherapy and surgery. Depending on the progression and location of cancer cells, they may recommend different options.
We'll help you or a loved one find the most qualified mesothelioma specialists and treatment facilities in your area.
At this point of early development, tumors are close to the original tumor, having only grown in one layer of the lining of the lungs (pleura). The cancer may also have grown into the covering of the heart and the diaphragm on the same side as it first formed.
The life expectancy for someone with stage I mesothelioma is significantly better that those with later stages, and these patients may live three years or longer. However, it is difficult to catch the cancer this early because people with this stage do not usually have symptoms.
Curative surgery to remove the tumor is considered the first line of treatment, and doctors usually recommend aggressive treatment that includes chemotherapy and radiotherapy.
Median life expectancy at stage I is 21 months.
Stage II symptoms are vague and mild. Patients — and even doctors — sometimes mistake them for signs of other illnesses like the flu. Patients with peritoneal mesothelioma may lose weight and yet feel bloated.
Several treatment options are available, and doctors can usually offer curative surgery to remove tumors. In studies, some patients diagnosed at this point survive for years.
Median life expectancy at stage II is 19 months.
Once the cancer progresses to stage III, it may have spread to several locations on the same side of the body as it formed. These areas may include the lymph nodes, esophagus, muscles, ribs, heart and the chest wall.
Pleural mesothelioma patients may suffer from more difficulty breathing and intense chest pain even when resting. Peritoneal mesothelioma usually involves some type of bowel obstruction and pain. Because the tumors have now spread to multiple areas of the body, discomfort may be felt in other parts of the body as well.
Tumors typically do not respond to potentially curative treatment, and some stage III cancer patients will find themselves ineligible for surgery. At that point, doctors offer palliative options.
Median life expectancy at stage III is 16 months.
About 30 percent of mesothelioma patients are not diagnosed until this stage. By stage IV, tumors have metastasized (spread) throughout the body via the bloodstream and could be present on the liver, in the brain, bones or elsewhere.
Patients experience extreme difficulty breathing and suffer from severe chest pain. Tumors can spread to the esophagus or stomach, causing digestive problems and difficulty swallowing or eating.
Doctor's don't recommend aggressive surgeries. Instead, they fall back on palliative treatments designed to ease pain and control symptoms.
Median life expectancy at stage IV is 12 months or less.
|Parietal pleura:||The lining of the chest cavity|
|Visceral pleura:||The lining of the lungs|
|Lung parenchyma:||Any form of lung tissue, including the bronchioles, bronchi, alveoli, interstitium and blood vessels|
|Mediastinal:||Affecting the mediastinum, the area between the lungs containing the heart, aorta, trachea esophagus and thymus|
|Diaphragmatic pleura:||The lining of the diaphragm, a primary breathing muscle|
|Peritoneum:||The lining of the abdominal cavity|
|Endothoracic fascia:||A layer of connective tissue that separates the ribs from the pleura|
|Pericardium:||The lining of the heart|
|Myocardium:||The muscle tissue of the heart|
|Diffuse:||Spread across a wide area|
|Multifocal:||Occurring in more than one location|
|Unresectable:||Not capable of being removed with surgery|
|Nontransmural:||Occurring not completely, but partially across the wall of an organ|
|Ipsilateral:||On the same side of the chest as where the cancer formed|
|Contralateral:||On the opposite side of the chest as where the cancer formed|
The Brigham staging system was created by Dr. David Sugarbaker at the Brigham and Women’s Hospital in Boston. With this system, doctors examine organs, tissues and other structures to learn how far the cancer has advanced.
Tumors are confined to the lining of the lungs and cancer has not spread to the lymph nodes.
Tumors are confined to the lining of the lungs. Either the intraparenchymal or mediastinal lymph nodes are cancerous.
Aggressive and unresectable tumors in the lining of the lungs have spread into the mediastinum or invaded the chest wall, diaphragm or contralateral lymph nodes.
Cancer has spread to other parts of the body and is unresectable.
Find out if you or a loved one qualifies for free mesothelioma medical care.
Doctors use the TNM system to stage many different types of cancer. In 1995, the International Mesothelioma Interest Group (IMIG) modified this system specifically for asbestos-related cancers because of the lack of a universally accepted staging system.
Also called the IMIG Staging System, this is the most widely used system for someone with pleural cancer. Doctors sometimes use it for other types as well. Earlier staging systems like the Butchart system and Brigham system were based largely on studies of patients who underwent extrapleural pneumonectomy.
The abbreviation TNM signifies three different parts of a diagnosis:
(T) describes tumor size and location.
(N) describes whether lymph nodes are affected.
(M) describes whether the tumors metastasized, or spread, to other parts of the body.
Doctors add a number after each letter to describe how far the cancer has advanced. As tumor size increases and the cancer invades more structures, the number increases.
T describes the size and location of the tumor:
The primary tumor cannot be assessed.
There is no evidence of a primary tumor.
The tumor is limited to the ipsilateral parietal pleura as well as the mediastinal and diaphragmatic pleura. There is no involvement of the visceral pleura.
The tumor has spread to the ipsilateral parietal and visceral pleura, along with the mediastinal and diaphragmatic pleura.
The ipsilateral pleural surfaces, which include the parietal, mediastinal, diaphragmatic and visceral pleura, have been invaded by tumors. At least one of the following features is also included in this stage:
The tumor has expanded locally, but can potentially be removed with surgery. It has invaded all of the ipsilateral pleural surfaces, which include the parietal, mediastinal, diaphragmatic and visceral pleura. One or more of the following features will be displayed:
The tumor is locally advanced and is unresectable. It has spread to all of the ipsilateral pleural surfaces including the parietal, mediastinal, diaphragmatic and visceral pleura. These tumors will also display at least one of the following features:
N describes whether the cancer has spread to glands of the immune system called lymph nodes:
|NX||The regional lymph nodes cannot be assessed.|
|N0||Cancer has not spread to the regional lymph nodes.|
|N1||Cancer has spread to the ipsilateral bronchopulmonary or hilar lymph nodes.|
|N2||Cancer has spread to the subcarinal or the ipsilateral mediastinal lymph nodes, which include the ipsilateral internal mammary nodes.|
|N3||Cancer has spread to the contralateral mediastinal, contralateral internal mammary, ipsilateral or contralateral supraclavicular lymph nodes.|
M indicates whether cancer has spread to other parts of the body. If the cancer has metastasized, that means it has spread, causing secondary tumors to grow in distant parts of the body away from where the first tumor formed.
|MX||The presence of metastasis cannot be assessed.|
|M0||The tumor has not metastasized to other parts of the body.|
|M1||Metastasis to other parts of the body has occurred.|
TNM stage grouping combines the tumor, node and metastasis values to reveal the cancer's stage.
|Stage||Primary Tumor (T)||Regional Lymph Nodes (N)||Metastasis (M)|
|Any T||Any N||M1|
Hear how survivors learned about their diagnosis and what steps they took to cope. Learn More
A former shipyard worker visits his doctor and complains of relatively mild symptoms including difficulty breathing and a feeling of heaviness in the chest. Because the patient presents with a history of exposure to asbestos on the job, the doctor suspects mesothelioma.
After conducting a series of tests, the doctor finds a tumor that involves the supporting tissues of the lung and the diaphragm (T2), but finds no evidence that the tumor has spread to the lymph nodes (N0) or other areas of the body (M0). The doctor would likely diagnose the patient with stage II mesothelioma.
The Butchart system is the oldest method of determining someone's pleural mesothelioma stage. Eric Butchart proposed this system in 1976 in an article for Thorax medical journal.
The Butchart system classifies tumors as stage I through IV using the same basic parameters as the TNM and Brigham systems.
Butchart intended his system to help identify which patients are good candidates for radical treatment. Again, only patients with stage I or II cancer are candidates for curative treatment, and palliative treatment is offered to patients in the two late stages.
This system also may help doctors determine prognosis. In four multivariate studies, early stage is listed as a sign of good prognosis. Two of the studies cited stage I disease as a highly favorable factor for survival.
The cancer affects the pleura on only one side of the chest, and may have spread to the pericardium and diaphragm. Curative surgery is considered a first-line treatment.
Cancer has spread to the chest wall and may affect both sides of the pleura. It may have spread to the esophagus, heart or lymph nodes of the chest. Butchart primarily recommends high-dose radiation therapy to most patients with stage II mesothelioma.
Cancer has spread to the diaphragm or peritoneum. Mesothelioma cells have also traveled through the lymphatic system to lymph nodes outside the chest. These tumors are generally unresponsive to curative therapies, so patients are introduced to their palliative options. Butchart suggests tube drainage for pleural effusions and delivery of chemotherapy drugs directly to the chest.
The cancer has spread through the bloodstream to distant parts of the body. Tumors may now be present on the liver, brain or bones, among other organs. Patients with stage IV mesothelioma are considered terminal and Butchart recommends solely palliative treatments.
Through a process known as tumor grading, doctors classify cancerous cells based on how they appear under a microscope. Researchers confirmed that cellular features of tumors can offer signs to help doctors better predict survival among mesothelioma patients.
One of several approaches to tumor grading is nuclear grading. The process classifies the size and shape of the nuclei in tumor cells while examining other factors, including nucleolus size, chromatin patterns and the rate of cell division. These variables play central roles in cancer cell genetics, and ongoing studies are exploring their clinical value as indicators of prognosis.
The nuclear grading system developed at Cleveland Clinic inspired other studies that investigated the connection between tumor grade and mesothelioma survival. In what turned out to be the strongest evidence supporting this relationship to date, researchers at Memorial Sloan-Kettering Cancer Center analyzed 232 cases of epithelioid diffuse malignant pleural mesothelioma for the following features:
The analysis proved that nuclear atypia (variations in cell nucleus appearance) and mitotic count (the number of cells actively dividing) were directly related to a patient's prognosis.
Severe nuclear atypia was found to drastically reduce overall survival, and a low mitotic count, which means that few cells are dividing and spreading, indicated the highest overall survival. Using this information, the researchers developed a three-tier nuclear grade score that divides patients into the following prognostic groups:
|Grade||Median Overall Survival|
|Grade 1||28 months|
|Grade 2||14 months|
|Grade 3||5 months|
The results of this study also showed tumor cell's chromatin, which is a combination of nuclear DNA and protein, was also linked to survival.
Not only was nuclear grade found to be a simple, cost-effective prognostic tool for determining overall survival, but it also helped predict the time to mesothelioma recurrence among patients treated with surgery. Patients with a low mitotic count averaged 67 months before their cancer returned, and those with a high mitotic count averaged 14 months.
View our resources for patients and familiesGet Help Today